Snoring: Labs, Diagnosis, and Next Steps

Why Snoring Happens: The Mechanics Behind the Noise

Snoring is produced when airflow through the upper airway causes vibration of relaxed pharyngeal tissues during sleep. The soft palate, uvula, tonsillar pillars, and tongue base narrow the airway, and turbulent airflow through this constricted space generates audible sound. Understanding the specific site of obstruction guides both testing and treatment.

Several anatomical and physiological factors contribute. A body mass index (BMI) above 30 kg/m² increases pharyngeal fat deposition and external airway compression 1. Nasal congestion from allergic rhinitis or septal deviation raises upstream resistance, pulling pharyngeal walls inward. Alcohol consumption within three hours of sleep relaxes the genioglossus muscle and worsens airway collapsibility 2. Aging reduces pharyngeal muscle tone. Male sex confers a two- to threefold higher prevalence of habitual snoring compared to premenopausal women, a gap that narrows after menopause 3.

The clinical question is not whether someone snores. It is whether snoring represents simple (primary) snoring or a marker of OSA. In the Wisconsin Sleep Cohort Study (N=1,522), 93% of women and 82% of men with moderate-to-severe OSA were undiagnosed at baseline 4. That statistic alone justifies a structured evaluation for anyone with chronic snoring.

When Snoring Requires Medical Evaluation

Not every snorer needs a sleep study. The red flags that should prompt evaluation are witnessed apneas (a bed partner observing breathing pauses), excessive daytime sleepiness, gasping or choking arousals, morning headaches, and nocturia. Any of these raises the pretest probability of OSA from background levels to clinically actionable territory.

The STOP-BANG questionnaire is the most widely validated screening tool for OSA in adults. It scores eight binary items: Snoring, Tiredness, Observed apneas, Pressure (hypertension), BMI >35, Age >50, Neck circumference >40 cm, and Gender (male). A score of 5 to 8 carries a sensitivity of 83.6% for moderate-to-severe OSA and 100% for severe OSA in surgical populations 5.

The American Academy of Sleep Medicine (AASM) recommends diagnostic testing for patients with symptoms suggestive of OSA, particularly those with cardiovascular comorbidities. Dr. Kannan Ramar, past president of the AASM, stated: "Untreated obstructive sleep apnea is associated with increased cardiovascular morbidity and mortality, and early identification through appropriate screening and testing is essential" 6.

A neck circumference above 17 inches in men or 16 inches in women independently predicts OSA. So does a Mallampati score of III or IV on oropharyngeal examination. These findings take seconds to assess and belong in any evaluation of a snoring patient.

The Sleep Study: Polysomnography vs. Home Testing

In-laboratory polysomnography (PSG) remains the gold standard for diagnosing sleep-disordered breathing. A full PSG records electroencephalography, electrooculography, chin and leg electromyography, airflow (nasal pressure transducer and thermistor), respiratory effort (thoracic and abdominal belts), pulse oximetry, body position, and snoring intensity. It provides the apnea-hypopnea index (AHI), the number of apneas and hypopneas per hour of sleep, which defines OSA severity.

An AHI of 5 to 14 events per hour is mild OSA. An AHI of 15 to 29 is moderate. An AHI of 30 or higher is severe. These thresholds, established by the AASM, drive treatment decisions 7.

Home sleep apnea testing (HSAT) offers a more accessible alternative for patients with a high pretest probability of moderate-to-severe OSA and no significant comorbidities (no heart failure, no chronic lung disease, no neuromuscular disease). HSAT devices typically measure airflow, respiratory effort, and oximetry. They record the respiratory event index (REI) rather than the AHI, because total sleep time is estimated rather than measured by EEG.

The AASM clinical practice guideline published in the Journal of Clinical Sleep Medicine recommends HSAT as an acceptable alternative to PSG for uncomplicated adult patients when interpreted by a board-certified sleep medicine physician 8. A negative or inconclusive HSAT in a symptomatic patient should be followed by in-lab PSG, because HSAT can underestimate severity.

Cost differences are significant. A facility-based PSG typically costs $1,800 to $5,000 before insurance, while HSAT ranges from $300 to $600. For patients with high deductible plans, HSAT can be a practical first step.

Lab Tests Every Snoring Patient Should Discuss

A sleep study diagnoses the breathing disorder. Bloodwork identifies the metabolic context around it. OSA and its common comorbidities share bidirectional relationships, and targeted labs reveal whether snoring is an isolated finding or part of a broader cardiometabolic picture.

Thyroid-stimulating hormone (TSH). Hypothyroidism causes macroglossia, mucosal edema of the upper airway, and decreased ventilatory drive. A TSH level can identify a reversible contributor to snoring. The Endocrine Society recommends screening for thyroid dysfunction in patients with newly diagnosed OSA 9.

Fasting glucose and HbA1c. The Sleep Heart Health Study (N=6,441) demonstrated a dose-response relationship between OSA severity and glucose intolerance, independent of adiposity 10. An HbA1c of 5.7% to 6.4% indicates prediabetes. Every snoring patient with a BMI above 25 warrants metabolic screening.

Lipid panel. OSA is independently associated with dyslipidemia. Intermittent hypoxia increases hepatic lipogenesis and raises LDL cholesterol and triglycerides 11.

Complete blood count (CBC). Polycythemia (elevated hematocrit) can develop from chronic nocturnal hypoxemia. A hematocrit above 52% in men or 48% in women suggests this compensatory response.

Basic metabolic panel. Serum bicarbonate elevation (above 27 mEq/L) in a snoring patient may indicate chronic CO₂ retention, pointing to obesity hypoventilation syndrome overlapping with OSA.

These tests do not diagnose snoring itself. They map the terrain of risk that surrounds it and shape the urgency of treatment.

CPAP: The First-Line Treatment for Obstructive Sleep Apnea

Continuous positive airway pressure therapy is the first-line treatment for moderate-to-severe OSA and remains the most studied intervention. CPAP delivers a pneumatic splint to the upper airway, preventing collapse during sleep. The pressure is titrated during a PSG or through auto-titrating (APAP) algorithms.

The SAVE trial (N=2,717), published in the New England Journal of Medicine, randomized patients with moderate-to-severe OSA and established cardiovascular disease to CPAP plus usual care versus usual care alone. Mean CPAP use was 3.3 hours per night. The trial did not show a reduction in major cardiovascular events over a mean follow-up of 3.7 years, though CPAP significantly improved daytime sleepiness, depression scores, and quality of life 12.

The adherence threshold matters. The Centers for Medicare and Medicaid Services (CMS) defines adherence as 4 or more hours per night on 70% of nights over a 30-day period. Patients who meet this threshold show consistent improvements in daytime function and blood pressure. A meta-analysis of 32 RCTs (N=4,899) found that CPAP reduced mean arterial blood pressure by 2.6 mmHg in patients with OSA 13.

Common reasons for CPAP discontinuation include mask discomfort, nasal dryness, aerophagia, and claustrophobia. Heated humidification, proper mask fitting, and a 30-day follow-up visit improve adherence. Modern CPAP devices transmit usage data wirelessly, allowing clinicians to monitor adherence remotely and intervene early.

Oral Appliances and Positional Therapy

For patients with mild-to-moderate OSA (AHI 5 to 30) who cannot tolerate CPAP, mandibular advancement devices (MADs) offer an evidence-based alternative. These custom-fitted dental appliances protrude the mandible forward by 6 to 10 mm, enlarging the retropalatal and retroglossal airway.

A Cochrane systematic review of 51 RCTs found that MADs reduced AHI by approximately 12 events per hour compared to placebo, though they were less effective than CPAP in AHI reduction 14. The AASM and American Academy of Dental Sleep Medicine joint guideline recommends MADs for adults with OSA who prefer them to CPAP or who are intolerant of CPAP therapy 15.

Custom-fabricated devices, fitted by a dentist trained in dental sleep medicine, outperform over-the-counter "boil and bite" appliances. Side effects include temporomandibular joint discomfort, tooth movement, and excessive salivation, which typically improve over weeks. Patients using MADs require dental follow-up every 6 months to assess occlusal changes.

Positional therapy applies to supine-predominant OSA, where the AHI is at least twice as high in the supine position compared to the lateral position. Commercially available positional devices (wearable vibrotactile trainers or foam wedges) keep the patient off their back. A randomized trial (N=99) comparing positional therapy to CPAP in supine-predominant mild-to-moderate OSA found equivalent improvements in AHI when patients adhered to their assigned therapy 16.

Weight Loss: The Modifier That Changes Everything

Obesity is the single strongest modifiable risk factor for OSA. The Wisconsin Sleep Cohort data showed that a 10% weight gain predicted a 32% increase in AHI, while a 10% weight loss predicted a 26% decrease 17.

The Sleep AHEAD study, an ancillary to the Look AHEAD trial (N=264 participants with type 2 diabetes and OSA), found that intensive lifestyle intervention producing 10.8 kg mean weight loss at one year reduced AHI by 9.7 events per hour, compared to a 0.6 events per hour increase in the diabetes support and education group 18.

Dr. Sanjay Patel, a sleep researcher at the University of Pittsburgh, has noted: "Weight loss should be part of the treatment plan for every overweight or obese patient with OSA, not as a replacement for CPAP, but as a concurrent intervention that may eventually reduce or eliminate the need for positive airway pressure" 19.

GLP-1 receptor agonists are changing this conversation. The SURMOUNT-OSA trial (N=469), published in the New England Journal of Medicine in 2024, demonstrated that tirzepatide 10 or 15 mg weekly reduced AHI by 25.3 events per hour (roughly 51.5% from baseline) in patients with moderate-to-severe OSA and obesity, compared to a 5.3 events per hour reduction with placebo 20. This is the largest AHI reduction demonstrated by any pharmacologic intervention in OSA to date.

For patients who qualify, bariatric surgery produces the greatest sustained weight loss. A meta-analysis of 69 studies (N=13,900) found that bariatric surgery reduced mean AHI from 54.7 to 15.8 events per hour, a 71% reduction 21.

Surgical Options for Snoring and OSA

Surgery is reserved for patients with identifiable anatomical obstruction who have failed or cannot tolerate CPAP and oral appliances. Drug-induced sleep endoscopy (DISE) allows the surgeon to visualize the site(s) and pattern of airway collapse under sedation, guiding procedure selection.

Uvulopalatopharyngoplasty (UPPP) removes redundant tissue from the soft palate, uvula, and lateral pharyngeal walls. A meta-analysis of 15 studies found a pooled success rate (defined as AHI reduction of 50% or more and final AHI <20) of 49.6% 22. UPPP is most effective for isolated palatal-level obstruction confirmed by DISE.

Hypoglossal nerve stimulation (Inspire therapy), FDA-approved in 2014, delivers electrical impulses to the hypoglossal nerve during inspiration, protruding the tongue and stiffening the airway. The STAR trial (N=126) showed a 68% reduction in median AHI at 12 months, sustained at 5-year follow-up 23. Candidates must have moderate-to-severe OSA (AHI 15 to 65), BMI <35, and absence of complete concentric collapse at the velum on DISE.

For primary snoring without OSA, radiofrequency ablation of the soft palate and laser-assisted uvuloplasty are office-based procedures with modest and variable efficacy. These reduce snoring loudness but do not reliably treat sleep apnea.

Building Your Action Plan: From Screening to Follow-Up

A structured clinical pathway prevents delays and missed diagnoses. The sequence matters.

Step 1: Screen. Complete the STOP-BANG questionnaire and Epworth Sleepiness Scale (ESS). An ESS score above 10 suggests clinically significant daytime sleepiness.

Step 2: Physical exam. Measure BMI, neck circumference, Mallampati score, and nasal patency. Inspect for tonsillar hypertrophy, retrognathia, and macroglossia.

Step 3: Sleep study. Order HSAT for uncomplicated patients with high pretest probability. Refer to in-lab PSG if HSAT is negative or inconclusive, or if cardiopulmonary comorbidities are present.

Step 4: Lab work. Obtain TSH, fasting glucose, HbA1c, lipid panel, CBC, and basic metabolic panel. Add an arterial blood gas if obesity hypoventilation is suspected (BMI >40 with daytime hypercapnia symptoms).

Step 5: Initiate treatment. For AHI of 15 or higher, start CPAP or APAP. For AHI of 5 to 14 with symptoms, offer CPAP or a mandibular advancement device. For primary snoring with no OSA, address modifiable factors (weight, alcohol, sleep position, nasal obstruction).

Step 6: Follow up. Reassess symptoms and device adherence at 30 days. Download CPAP data or request a follow-up sleep study with the oral appliance in place. Repeat the ESS. Schedule follow-up every 3 to 6 months for the first year, then annually.

Patients with an AHI of 30 or higher and an oxygen nadir below 80% on their sleep study should receive treatment urgently, as severe OSA with significant desaturations carries a hazard ratio of 3.8 for cardiovascular events compared to age-matched controls without OSA 24.